💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Acetophenazine

CHEMBL1085 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
411.6 g/mol
LogP
2.6
Phase
4

Dopamine D2 receptors in the mesolimbic pathway are the principal target of acetophenazine, a phenothiazine antipsychotic used for schizophrenia and related severe psychiatric illness. Reducing excessive dopaminergic transmission along that pathway diminishes hallucinations, delusions and disorganised thinking. Antagonism at serotonin 5-HT2A receptors accompanies the dopaminergic action in many agents of this family and is thought to influence negative symptoms and the liability to movement disorder. Extrapyramidal effects, including tremor and involuntary movement, remain the characteristic burden of the class, and newer antipsychotics with better tolerability have largely displaced it from current practice. The molecule is a small molecule with the formula C23H29N3O2S and a mass near 411.6 g/mol.

An older antipsychotic medication from the phenothiazine class that was used to treat schizophrenia and other serious psychiatric conditions by blocking dopamine receptors in the brain. It reduces hallucinations, delusions, and disorganized thinking but carries a risk of movement-related side effects known as extrapyramidal symptoms, including tremors and involuntary muscle movements. It has been largely superseded by newer antipsychotic medications with improved tolerability profiles.

Молекулярная масса

411,6000 g/mol

LogP

2,60

TPSA

72,30 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Psychiatry Schizophrenia

Механизм действия

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2

                

                

                
                

                    
InChI

                    
InChI=1S/C23H29N3O2S/c1-18(28)19-7-8-23-21(17-19)26(20-5-2-3-6-22(20)29-23)10-4-9-24-11-13-25(14-12-24)15-16-27/h2-3,5-8,17,27H,4,9-16H2,1H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C23H29N3O2S

                    

                    
                    

                        
HBD / HBA

                        
1 / 6

                    

                    
                    

                        
Вращаемые Связи

                        
7

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
29

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
An older antipsychotic medication from the phenothiazine class that was used to treat schizophrenia and other serious psychiatric conditions by blocking dopamine receptors in the brain. It reduces hallucinations, delusions, and disorganized thinking but carries a risk of movement-related side effects known as extrapyramidal symptoms, including tremors and involuntary muscle movements. It has been largely superseded by newer antipsychotic medications with improved tolerability profiles.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Acetophenazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1085.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 17676.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.